A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Part of paid clinical trials in Springdale, Arkansas.
- Sponsor
- Daiichi Sankyo
- Study ID
- NCT06203210
- Phase
- PHASE3
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ifinatamab deruxtecan — DRUG12 mg/kg intravenous dose on Day 1 of each 21-day cycle
- Topotecan — DRUGTopotecan will be administered per local SoC.
- Amrubicin — DRUGAmrubicin will be administered per local SoC.
- Lurbinectedin — DRUGLurbinectedin will be administered per local SoC
Study Details
This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
Key Dates
- Start date
- May 21, 2024
- Status verified
- May 2026
- Primary completion
- Apr 30, 2027
- Completion
- Feb 22, 2029
Study Design
- Enrollment
- 540 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Ifinatamab deruxtecan (I-DXd)Participants randomized to receive 12 mg/kg I-DXd monotherapy on Day 1 of each 21-day cycle until unacceptable toxicity, progressive disease (PD), or withdrawal of consent as specified in the protocol.
- Active Comparator: Treatment of Physician's Choice (TPC)Participants randomized to receive topotecan, lurbinectedin, or amrubicin, as per investigator's choice and per locally approved label (indicated dose and frequency), until a treatment discontinuation criterion is met as specified in the protocol.
Primary Outcome Measure
Number of Participants With Objective Response Rate Assessed by Blinded Independent Central Review [ Time Frame: Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 5 years ]
Central Contacts
- Daiichi Sankyo Contact for Clinical Trial Information9089926400
Locations (30)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Highlands Oncology Group | Springdale | Arkansas | 72762 | Principal Investigator |
| Clinical Research Providence Medical Foundation | Fullerton | California | 92835 | Principal Investigator |
| UCLA Hematology-Oncology | Los Angeles | California | 90095 | Principal Investigator |
| UCSF Mission Bay Mission Hall | San Francisco | California | 94115 | Principal Investigator |
| University of Miami Hospital and Clinics Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | Principal Investigator |
| AdventHealth Orlando, Cancer Institute | Orlando | Florida | 32804 | Principal Investigator |
| H. Lee Moffitt Cancer Center and Research Institute, Inc | Tampa | Florida | 33612 | Principal Investigator |
| Rush MD Anderson Cancer Center | Chicago | Illinois | 60612 | Principal Investigator |
| Baptist Health Lexington | Lexington | Kentucky | 40503 | Principal Investigator |
| John Hopkins School of Medicine | Baltimore | Maryland | 21287 | Principal Investigator |
| University of Maryland Greenebaum Comprehensive Cancer Center | Baltimore | Maryland | 21201 | Principal Investigator |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02216 | Principal Investigator |
| Henry Ford Health System | Detroit | Michigan | 48202 | Principal Investigator |
| Mercy Clinic Oncology and Hematology Sindelar Cancer Center | St Louis | Missouri | 63128 | Principal Investigator |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198-6811 | Principal Investigator |
| Dartmouth-Hitchcock Medical Center | Lebanon | New Hampshire | 03766 | Principal Investigator |
| Astera Cancer Care | East Brunswick | New Jersey | 08816 | Principal Investigator |
| Hackensack Meridian Health Jsumc | Neptune City | New Jersey | 07753 | Principal Investigator |
| Clinical Research Alliance, Inc | Lake Success | New York | 11042 | Principal Investigator |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone Health Long Island | New York | New York | 10016 | Principal Investigator |
| New York University Cancer Center - Laura and Isaac | New York | New York | 10016 | - |
| Montefiore Medical Center Prime | The Bronx | New York | 10461 | Principal Investigator |
| Cleveland Clinic Mercy Hospital | Canton | Ohio | 44708 | Principal Investigator |
| Oncology/Hematology Care Clinical Trials, Llc | Cincinnati | Ohio | 45236 | Principal Investigator |
| Providence Portland Medical Center | Portland | Oregon | 97213 | Principal Investigator |
| THE WEST CLINIC, PLLC dba West Cancer Center | Germantown | Tennessee | 38138 | Principal Investigator |
| Houston Methodist Cancer Center | Houston | Texas | 77030 | Principal Investigator |
| University of Texas Md Anderson Cancer Center | Houston | Texas | 77030 | Principal Investigator |
| Texas Oncology, P.A. - Tyler | Tyler | Texas | 75702 | Principal Investigator |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | Principal Investigator |
Find similar trials in Springdale, AR
By condition
By specialty
By research site
Highlands Oncology Group· Springdale, ARClinical Research Providence Medical Foundation· Fullerton, CAUCLA Hematology-Oncology· Los Angeles, CAUCSF Mission Bay Mission Hall· San Francisco, CAUniversity of Miami Hospital and Clinics Sylvester Comprehensive Cancer Center· Miami, FLAdventHealth Orlando, Cancer Institute· Orlando, FL
Related Studies
- Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial TumorsRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56PHASE1/PHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · New York, New York
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1/PHASE2 · Recruiting · PMV Pharmaceuticals, Inc · Irvine, California
- TEMPUS Small Cell Lung Cancer OBSERVATIONAL STUDY (Sculptor)Recruiting · Tempus AI · Los Alamitos, California